Charite Dept Urol Charitepl 1 D-10117 Berlin GermanyEuropean urologyMiller K, Carles J, Gschwend JE et al. The Phase 3 COU-AA-302 Study of abiraterone acetate plus prednisone in men with chemotherapy-na€ive metastatic castration-resistant prostate cancer: stratified analysis based on pain, ...
Journal Club: Final OS Analysis of COU-AA-302 - Study of Abiraterone Acetate in mCRPC without Prior Chemo Charles Ryan, MD discusses the preservation of function, the prevention of symptoms, and the prolongation of overall survival from this final analysis of the COU-AA-302...
Final Overall Survival Analysis of COU-AA-302, a Randomized Phase 3 Study of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients without Prior Chemotherapy Charles Ryan, MD presents a final analysis of the COU-AA-302 study which has demonstrated a statisticall...
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Eur Urol. 2017 Sep 20. https:/ / doi.org/10.1016/j.eururo.2017.08...
Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman- May SD. The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-nai篓ve metastatic castration- resistant prostate cancer (mCRPC): stratified analysis based on pain, prostate-specific antigen...
PD27-01 EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCERINTRODUCTION AND OBJECTIVES Abiraterone (AA), a specific CYP17 inhibitor, plus prednisone (P) significantly improves radiographic ...
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Charles J. Ryan,Matthew Raymond Smith,Johann Sebastian De Bono,Arturo Molina,Christopher ...
P. MainwaringElsevierMulders P, Van Poppel H, Rathkopf D, et al. Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abi- raterone acetate (AA) in metastatic castration-resistant prostate can- cer (mCRPC) patients (pts) without prior chemotherapy. Paper ...